首页|膜联蛋白A5在缺血性卒中诊疗中的研究进展

膜联蛋白A5在缺血性卒中诊疗中的研究进展

扫码查看
缺血性卒中是导致我国中老年人群残疾和死亡的重要病因之一,从诊断到治疗需要面临许多复杂的问题。目前,血管再通治疗已成为缺血性卒中最重要的治疗方法。但是,单纯行血管再通治疗后,部分患者的预后仍不理想。此外,目前针对单一靶点的神经保护药物治疗缺血性卒中的效果仍不显著。膜联蛋白A5具有多种生物学功能,其抗凝血、抗炎症、促进神经元存活等功能可用于减轻脑血管再通后再灌注损伤等神经保护治疗。膜联蛋白A5因其与磷脂酰丝氨酸具有紧密结合特性,可用于卒中诊断、靶向治疗载体构建等。作者总结膜联蛋白A5的多种功能,分析其在缺血性卒中中可能产生的影响,以期为后续研究提供参考。
Research progress of annexin A5 in diagnosis and treatment of ischemic stroke
Ischemic stroke is one of the important causes of disability and death among middle-aged and elderly people in China,and there are many complicated problems from diagnosis to treatment.At present,vascular recanalization has become the most important treatment for ischemic stroke.However,the prognosis of patients is still not ideal after vascular recanalization treatment alone.At the same time,the therapeutic effect of neuroprotective drugs targeting a single target is still not significant.Annexin A5 has many biological functions,such as anticoagulation,anti-inflammation,protection of neuron survival and so on,and can be used for neuroprotective therapy such as reducing reperfusion injury after cerebral vascular recanalization.Annexin A5 can be used in the diagnosis of stroke and the construction of targeted vectors because of its close binding with phosphatidylserine.The authors summarized the multiple functions of Annexin A5,and analyzes its possible effects on ischemic stroke,so as to provide reference for the follow-up study.

Ischemic strokeAnnexin VEmbolismInflammationReview

朱占伟、何嘉琛、郭佳琦、徐率立、吴迪

展开 >

100053 北京,首都医科大学宣武医院中美神经科学研究所

缺血性卒中 膜联蛋白A5 栓塞 炎症 综述

国家自然科学基金国家自然科学基金

8237147082071466

2024

中国脑血管病杂志
中国医师协会 首都医科大学宣武医院

中国脑血管病杂志

CSTPCD北大核心
影响因子:1.076
ISSN:1672-5921
年,卷(期):2024.21(7)